Repare Therapeutics Out-Licenses Its Discovery Platforms To DCx Biotherapeutics; Will Receive $4M Upfront And 9.99% Common Equity Position In DCx And Is Eligible For Milestone Payments And Royalties

BenzingaMay 1 07:14 ET

Express News | Repare Therapeutics Announces Out-Licensing of Its Discovery Platforms to Dcx Biotherapeutics

ReutersMay 1 07:00 ET

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

BusinesswireMay 1 07:00 ET

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry

Simply Wall StApr 29 06:22 ET

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

BusinesswireApr 25 13:00 ET

B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating

MT NewswiresApr 21 08:52 ET · Ratings